Author: Shaefi, Shahzad; Brenner, Samantha K.; Gupta, Shruti; O’Gara, Brian P.; Krajewski, Megan L.; Charytan, David M.; Chaudhry, Sobaata; Mirza, Sara H.; Peev, Vasil; Anderson, Mark; Bansal, Anip; Hayek, Salim S.; Srivastava, Anand; Mathews, Kusum S.; Johns, Tanya S.; Leonberg-Yoo, Amanda; Green, Adam; Arunthamakun, Justin; Wille, Keith M.; Shaukat, Tanveer; Singh, Harkarandeep; Admon, Andrew J.; Semler, Matthew W.; Hernán, Miguel A.; Mueller, Ariel L.; Wang, Wei; Leaf, David E.
Title: Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19 Cord-id: chka639p Document date: 2021_2_2
ID: chka639p
Snippet: PURPOSE: Limited data are available on venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe hypoxemic respiratory failure from coronavirus disease 2019 (COVID-19). METHODS: We examined the clinical features and outcomes of 190 patients treated with ECMO within 14 days of ICU admission, using data from a multicenter cohort study of 5122 critically ill adults with COVID-19 admitted to 68 hospitals across the United States. To estimate the effect of ECMO on mortality, we em
Document: PURPOSE: Limited data are available on venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe hypoxemic respiratory failure from coronavirus disease 2019 (COVID-19). METHODS: We examined the clinical features and outcomes of 190 patients treated with ECMO within 14 days of ICU admission, using data from a multicenter cohort study of 5122 critically ill adults with COVID-19 admitted to 68 hospitals across the United States. To estimate the effect of ECMO on mortality, we emulated a target trial of ECMO receipt versus no ECMO receipt within 7 days of ICU admission among mechanically ventilated patients with severe hypoxemia (PaO(2)/FiO(2) < 100). Patients were followed until hospital discharge, death, or a minimum of 60 days. We adjusted for confounding using a multivariable Cox model. RESULTS: Among the 190 patients treated with ECMO, the median age was 49 years (IQR 41–58), 137 (72.1%) were men, and the median PaO(2)/FiO(2) prior to ECMO initiation was 72 (IQR 61–90). At 60 days, 63 patients (33.2%) had died, 94 (49.5%) were discharged, and 33 (17.4%) remained hospitalized. Among the 1297 patients eligible for the target trial emulation, 45 of the 130 (34.6%) who received ECMO died, and 553 of the 1167 (47.4%) who did not receive ECMO died. In the primary analysis, patients who received ECMO had lower mortality than those who did not (HR 0.55; 95% CI 0.41–0.74). Results were similar in a secondary analysis limited to patients with PaO(2)/FiO(2) < 80 (HR 0.55; 95% CI 0.40–0.77). CONCLUSION: In select patients with severe respiratory failure from COVID-19, ECMO may reduce mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00134-020-06331-9.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and additional outcome: 1
- acute ards respiratory distress syndrome and low frequency: 1
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lung protective strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute ards respiratory distress syndrome and lung ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute care and additional analysis: 1
- acute care and additional outcome: 1
- acute care and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute care and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute care and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- acute care and lung protective strategy: 1, 2, 3, 4
- acute care and lung ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute care facility and low incidence: 1
- acute care facility and lung ventilation: 1
- acute kidney injury and additional analysis: 1
- acute kidney injury and low frequency: 1
- acute kidney injury and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
Co phrase search for related documents, hyperlinks ordered by date